Vol. 17 No. 2 (2018): Mapana Journal of Sciences
Research Articles

Alzheimer’s Disease: A Challenge In The Face Of Modern Era

PDF
  • Anil K Agarwal,
  • Roshni Varghese,
  • Gowri Soman,
  • K Krishna Kumar,
  • Joyal Joshy
Anil K Agarwal
CHRIST (Deemed to be University), Bengaluru.
Bio
Roshni Varghese
CHRIST (Deemed to be University), Bengaluru.
Bio
Gowri Soman
CHRIST (Deemed to be University), Bengaluru.
Bio
K Krishna Kumar
CHRIST (Deemed to be University), Bengaluru.
Bio
Joyal Joshy
CHRIST (Deemed to be University), Bengaluru.
Bio
DOI: https://doi.org/10.12723/mjs.45.3

Published 2021-08-16

Keywords

  • Alzheimer,
  • β-amyloid,
  • β-secretase,
  • BACE1,
  • Blood-brain barrier (BBB)

Copyright (c) 2018

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Abstract

Alzheimer’s disease (AD) is a devastating disease which affects the mental capacity and hence the standard of life of patients suffering from this disease. The accumulation of β-amyloid plaques and tau tangles has been found to be central to the disease. Over the years, research on β-secretase has become known as a hopeful target for the exploration of AD. A number of drugs have been approved by the US-FDA which meliorates only some of the symptoms of AD, but do not help in modifing the principal disease mechanisms.

PDF

References

  1. B. Duthey, “Alzheimer‟s disease and other dementias,” WHO, 2004.
  2. C. L. Masters, et al. (2015). "Alzheimer's disease." Nat Rev Dis Primers 1: 15056.
  3. S .Shanker, “Role of genomic copy number variation in alzheimer‟s disease and mild cognitive impairment, Indiana University”, August 2012.
  4. K. G. Arun, “Aspartic Acid Proteases as Therapeutic Targets”, Wiley, 2010.
  5. K. G.Arun and L. Heather Osswald, “BACE1 (b-secretase) inhibitors for the treatment of Alzheimer‟s disease.”
  6. K. G. Arun et al. “Potent Memapsin 2 (β-Secretase) Inhibitors: Design, Synthesis, Protein-Ligand X-ray Structure and in vivo Evaluation,” Bioorg. Med. Chem. Lett.Vol. 18(3): 1031–1036, 2008.
  7. R.T.Turner, J.A. Loy,C.Nguyen, T.Devasamudram, A.K.Ghosh, G. Koelsch and J.Tang, “Specificity of memapsin 1 and its implications on the design of memapsin 2 ( b-secretase) inhibitor selectivity”, Biochemistry, 41, 8742–8746, 2002.
  8. Lin Hong et al.,“Structure of the protease domain of memapsin-2 (beta secretase) complexed with inhibitor,”Science, vol.290, 150-3, 2000;
  9. J.J.NTang,G. Koelsch andA.K. Ghosh Inhibitors of memapsin 2 and their use in Alzheimer‟s disease treatment, WO2002053594, 2002.
  10. W. J. Lee et al. "Plasma MCP-1 and Cognitive Decline in Patients with Alzheimer's Disease and Mild Cognitive Impairment: A Two-year Follow-up Study." Sci Rep 8(1): 1280, 2018.
  11. G. F.Chen, et al. "Amyloid beta: structure, biology and structure-based therapeutic development." ActaPharmacol Sin 38(9): 1205-1235, 2017.
  12. Iqbal, K., et al. "Tau pathology in Alzheimer disease and other tauopathies." BiochimBiophysActa,vol.1739(2-3): 198-210, 2005.
  13. M. Gejl, et al. "Blood-Brain Glucose Transfer in Alzheimer's disease: Effect of GLP-1 Analog Treatment." Sci Rep 7(1): 17490, 2017.
  14. H.Zhu, et al. "Impairments of spatial memory in an Alzheimer's disease model via degeneration of hippocampal cholinergic synapses." Nat Commun, 8(1): 16762017.
  15. Doody, R. S., et al. (2014). "Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease." N Engl J Med, 370(4): 311-321
  16. L. S.Honig, et al. "Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease." N Engl J Med, 378(4): 321-330, 2018.
  17. S.Salloway, et al. "Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease." N Engl J Med, 370(4): 322-333, 2014.
  18. R. S.Doody, et al. "A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease." New England Journal of Medicine 369(4): 341-350, 2013.